Recently, rapid clinical progress of cancer immunotherapy with chimeric antigen receptor-modified T cells, or immune modulation using antibodies targeting the programmed death 1 (PD-1)–programmed death-ligand 1 (PD-L1) pathway, has underscored the importance of anti-tumor immunity in cancer therapy6–8. This evidence concerns the gene CD274 and cancer.